Valuation dashboard for Forte Biosciences, Inc. (FBRX) with P/E N/A, P/B 9.96, EV/EBITDA -17.71 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $76.99, FBRX has negative trailing earnings (P/E not meaningful) and an ROE of -94.82%. Market capitalisation stands at $1.6B.
Balance sheet quality for FBRX: current ratio of 3.9. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 9.96 |
| EV / EBITDA | -17.71 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $4.70 |
| vs Current Price | -93.9% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| FBRX | Forte Biosciences, Inc. | $1.6B | 9.96 | -94.8% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $76.99 |
| Market Cap | $1.6B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -94.82% |
| Return on Invested Capital | -48.53% |
| Return on Assets | -42.74% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACTU · ALEC · APLT · CRBP · CRDF · ELTX · FATE
Explore sector: Healthcare · Biotechnology
More sections of FBRX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks